Scolaris Content Display Scolaris Content Display

Agonistas dopaminérgicos para la prevención del síndrome de hiperestimulación ovárica

Esta versión no es la más reciente

ver la versión actual 14 abril 2021

Appendices

Appendix 1. Gynaecology and Fertility (formerly MDSG) search string

PROCITE Platform

From inception until 15 August 2016

Keywords CONTAINS "ovarian hyperstimulation syndrome " or "ovarian hyperstimulation" or "OHSS" or Title CONTAINS "ovarian hyperstimulation syndrome " or "ovarian hyperstimulation" or "OHSS"

AND

Keywords CONTAINS "cabergoline" or "Dopamine agonists" or "Dopamine" or "bromocriptine" or "quinagolide" or Title CONTAINS "cabergoline" or "Dopamine agonists" or "Dopamine" or "bromocriptine" or "quinagolide" (36 hits)

Appendix 2. CENTRAL search strategy

CRSO Web platform

from inception until 15 August 2016

#1 MESH DESCRIPTOR Ovarian Hyperstimulation Syndrome EXPLODE ALL TREES 163

#2 OHSS:TI,AB,KY 274

#3 (Ovar* adj2 Hyperstimulation):TI,AB,KY 902

#4 #1 OR #2 OR #3 968

#5 MESH DESCRIPTOR Ergolines EXPLODE ALL TREES 925

#6 Ergoline*:TI,AB,KY 237

#7 cabergoline:TI,AB,KY 171

#8 (Dostinex or Cabaser*):TI,AB,KY 4

#9 (Dopamine Agonist*):TI,AB,KY 937

#10 MESH DESCRIPTOR Dopamine Agonists EXPLODE ALL TREES 1449

#11 MESH DESCRIPTOR Bromocriptine EXPLODE ALL TREES 455

#12 Bromocriptine:TI,AB,KY 844

#13 quinagolide*:TI,AB,KY 17

#14 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 2461

#15 #4 AND #14 38

Appendix 3. MEDLINE search strategy

OVID platform

From 1946 to 15 August 2016

1 exp Ovarian Hyperstimulation Syndrome/ (1962)
2 OHSS.tw. (1420)
3 (Ovar$ adj2 Hyperstimulation).tw. (4387)
4 or/1‐3 (4799)
5 exp Ergolines/ (20838)
6 cabergoline.tw. (1215)
7 Ergoline$.tw. (546)
8 (Dostinex or Cabaser$).tw. (13)
9 Dopamine Agonist$.tw. (6908)
10 exp Dopamine Agonists/ (27910)
11 exp Bromocriptine/ (6867)
12 Bromocriptine.tw. (6547)
13 quinagolide$.tw. (117)
14 or/5‐13 (43020)
15 4 and 14 (105)
16 randomized controlled trial.pt. (428367)
17 controlled clinical trial.pt. (91556)
18 randomized.ab. (366942)
19 placebo.tw. (182638)
20 clinical trials as topic.sh. (178949)
21 randomly.ab. (261578)
22 trial.ti. (160440)
23 (crossover or cross‐over or cross over).tw. (70771)
24 or/16‐23 (1085156)
25 (animals not (humans and animals)).sh. (4266646)
26 24 not 25 (999370)
27 26 and 15 (41)

Appendix 4. Embase search strategy

OVID platform

From 1974 to 15 August 2016

1 exp ovary hyperstimulation/ (7481)
2 (ovar$ adj2 hyperstimulation).tw. (6125)
3 OHSS.tw. (2299)
4 or/1‐3 (9268)
5 cabergoline.tw. (1762)
6 exp ergoline derivative/ (990)
7 ergoline$.tw. (638)
8 (Dostinex or Cabaser$).tw. (347)
9 exp dopamine receptor stimulating agent/ or exp cabergoline/ (172347)
10 (dopamine adj2 agent$).tw. (509)
11 (dopamine adj2 agonist$).tw. (12113)
12 quinagolide$.tw. (170)
13 exp bromocriptine/ (17941)
14 bromocriptine.tw. (7195)
15 or/5‐14 (174581)
16 Clinical Trial/ (862238)
17 Randomized Controlled Trial/ (413467)
18 exp randomization/ (71619)
19 Single Blind Procedure/ (22711)
20 Double Blind Procedure/ (130713)
21 Crossover Procedure/ (48263)
22 Placebo/ (279471)
23 Randomi?ed controlled trial$.tw. (141716)
24 Rct.tw. (21228)
25 random allocation.tw. (1552)
26 randomly allocated.tw. (25411)
27 allocated randomly.tw. (2146)
28 (allocated adj2 random).tw. (762)
29 Single blind$.tw. (17830)
30 Double blind$.tw. (164731)
31 ((treble or triple) adj blind$).tw. (580)
32 placebo$.tw. (237405)
33 prospective study/ (346790)
34 or/16‐33 (1604891)
35 case study/ (39627)
36 case report.tw. (312069)
37 abstract report/ or letter/ (969653)
38 or/35‐37 (1314128)
39 34 not 38 (1563365)
40 4 and 15 and 39 (97)

Appendix 5. PsycINFO search strategy

OVID platform

From 1806 to 15 August 2016

1 Ovarian Hyperstimulation Syndrome.tw. (4)
2 OHSS.tw. (6)
3 (Ovar$ adj2 Hyperstimulation).tw. (10)
4 or/1‐3 (14)
5 exp dopamine agonists/ (19735)
6 cabergoline.tw. (114)
7 Ergoline$.tw. (45)
8 (Dostinex or Cabaser$).tw. (2)
9 Dopamine Agonist$.tw. (2260)
10 Bromocriptine.tw. (660)
11 exp bromocriptine/ (292)
12 quinagolide$.tw. (5)
13 or/5‐12 (21063)
14 4 and 13 (0)

Appendix 6. CINAHL

EBSCO platform

From inception until 15 August 2016

#

Query

Results

S14

S4 AND S13

11

S13

S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12

1,805

S12

TX quinagolide*

4

S11

TX Bromocriptine

303

S10

(MM "Bromocriptine")

97

S9

TX (Dostinex or Cabaser*)

1

S8

TX cabergoline

110

S7

TX Dopamine Agonist*

1,487

S6

(MM "Dopamine Agonists+")

822

S5

TX Ergoline*

14

S4

S1 OR S2 OR S3

362

S3

TX (Ovar* N2 Hyperstimulation)

352

S2

TX OHSS

79

S1

(MM "Ovarian Hyperstimulation Syndrome")

140

Appendix 7. ICTRP

Web platform

15 August 2016

OHSS AND dopamine OR cabergoline OR quinagolide OR bromocriptine (75 hits)

Appendix 8. Clinicaltrials.gov

Web platform

15 August 2016

OHSS AND dopamine OR cabergoline OR quinagolide OR bromocriptine (46 hits)

Appendix 9. PubMed

Web platform

15 August 2016

OHSS[Title/Abstract] AND (dopamine[Title/Abstract] OR cabergoline[Title/Abstract] OR quinagolide[Title/Abstract]) AND Clinical Trial[ptyp] (12 hits)

Appendix 10. Data extraction form

General trial characteristics

First author

Publish year

Citation:

Contact author detail:

Eligibility

1. Is the study an RCT?

2. High‐risk Women?

3. How OHSS defined?

4. Administration of cabergoline?

Decision: If all replies yes means include, otherwise exclude

Characteristics of the included studies

Risk of bias

  1. sequence generation (low, high or unclear)

  2. allocation concealment (low, high or unclear)

  3. blinding of participants (low, high or unclear)

  4. personnel and outcome assessors (low, high or unclear)

  5. incomplete outcome data, and selective outcome reporting (low, high or unclear)

Methods

Inclusion criteria:

Exclusion criteria:

Participants

Total number:

Diagnosis criteria:

Age (mean ± SD): treat group vs control group:

BMI (mean ± SD): treat group vs control group:

Duration of infertility:

Causes of infertility:

 

Interventions

Treat group:(dose, administration of drug, duration of treatment)

Control group (placebo or no intervention):

Outcomes

  1. Incidence of moderate and / or severe OHSS

  2. Incidence of early and / or late OHSS

  3. Live Birth rate

  4. Any other adverse effects of the treatment

  5. Miscarriage rate

  6. Implantation rate

  7. Clinical pregnancy rate

  8. Multiple pregnancy rate

Results

  • Number of participants allocated to each intervention group.

For each outcome of interest:

  • Sample size.

  • Missing participants*.

  • Summary data for each intervention group (e.g. 2x2 table for dichotomous data).

  • [Estimate of effect with confidence interval; P value].

  • [Subgroup analyses].

 

Miscellaneous

  • Funding source.

  • Key conclusions of the study authors.

  • Miscellaneous comments from the study authors.

  • References to other relevant studies.

  • Correspondence required.

  • Miscellaneous comments by the review authors.

 BMI: body mass index; OHSS: ovarian hyperstimulation syndrome; RCT: randomised controlled trial; SD: standard deviation.

Study flow diagram search August 2016.
Figuras y tablas -
Figure 1

Study flow diagram search August 2016.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison 1: Dopamine agonist (without co‐intervention) versus placebo/no intervention, outcome: 1.1 moderate or severe ovarian hyperstimulation syndrome.
Figuras y tablas -
Figure 4

Forest plot of comparison 1: Dopamine agonist (without co‐intervention) versus placebo/no intervention, outcome: 1.1 moderate or severe ovarian hyperstimulation syndrome.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: 2 Dopamine agonist plus co‐intervention versus co‐intervention, outcome: 2.1 Moderate or severe ovarian hyperstimulation syndrome.
Figuras y tablas -
Figure 5

Forest plot of comparison: 2 Dopamine agonist plus co‐intervention versus co‐intervention, outcome: 2.1 Moderate or severe ovarian hyperstimulation syndrome.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison 3: Cabergoline versus active interventions, outcome: 3.1 moderate or severe ovarian hyperstimulation syndrome.
Figuras y tablas -
Figure 6

Forest plot of comparison 3: Cabergoline versus active interventions, outcome: 3.1 moderate or severe ovarian hyperstimulation syndrome.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 1 Moderate or severe ovarian hyperstimulation syndrome (OHSS).
Figuras y tablas -
Analysis 1.1

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 1 Moderate or severe ovarian hyperstimulation syndrome (OHSS).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 2 Subgroup analysis by severity of OHSS.
Figuras y tablas -
Analysis 1.2

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 2 Subgroup analysis by severity of OHSS.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 3 Live birth.
Figuras y tablas -
Analysis 1.3

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 3 Live birth.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 4 Clinical pregnancy rate.
Figuras y tablas -
Analysis 1.4

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 4 Clinical pregnancy rate.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 5 Multiple pregnancy.
Figuras y tablas -
Analysis 1.5

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 5 Multiple pregnancy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 6 Miscarriage.
Figuras y tablas -
Analysis 1.6

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 6 Miscarriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 7 Adverse events.
Figuras y tablas -
Analysis 1.7

Comparison 1 Dopamine agonist versus placebo/no intervention, Outcome 7 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 1 Moderate or severe ovarian hyperstimulation syndrome (OHSS).
Figuras y tablas -
Analysis 2.1

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 1 Moderate or severe ovarian hyperstimulation syndrome (OHSS).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 2 Live birth.
Figuras y tablas -
Analysis 2.2

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 2 Live birth.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 3 Clinical pregnancy rate.
Figuras y tablas -
Analysis 2.3

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 3 Clinical pregnancy rate.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 4 Multiple pregnancy.
Figuras y tablas -
Analysis 2.4

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 4 Multiple pregnancy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 5 Miscarriage.
Figuras y tablas -
Analysis 2.5

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 5 Miscarriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 6 Adverse events.
Figuras y tablas -
Analysis 2.6

Comparison 2 Dopamine agonist plus co‐intervention versus co‐intervention, Outcome 6 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dopamine agonist versus active interventions, Outcome 1 Moderate or severe ovarian hyperstimulation syndrome (OHSS).
Figuras y tablas -
Analysis 3.1

Comparison 3 Dopamine agonist versus active interventions, Outcome 1 Moderate or severe ovarian hyperstimulation syndrome (OHSS).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dopamine agonist versus active interventions, Outcome 2 Clinical pregnancy rate.
Figuras y tablas -
Analysis 3.2

Comparison 3 Dopamine agonist versus active interventions, Outcome 2 Clinical pregnancy rate.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dopamine agonist versus active interventions, Outcome 3 Multiple pregnancy.
Figuras y tablas -
Analysis 3.3

Comparison 3 Dopamine agonist versus active interventions, Outcome 3 Multiple pregnancy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dopamine agonist versus active interventions, Outcome 4 Miscarriage.
Figuras y tablas -
Analysis 3.4

Comparison 3 Dopamine agonist versus active interventions, Outcome 4 Miscarriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings for the main comparison. Dopamine agonist versus placebo/no intervention

Dopamine agonist vs placebo/no intervention

Patient or population: women of reproductive age undergoing any ART therapy

Settings: ART unit

Intervention: dopamine agonist

Comparison: placebo/no intervention

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo/no intervention

Risk with dopamine agonist

Incidence of moderate or severe OHSS

286 per 1000

97 per 1000

(71 to 135)

OR 0.27

(0.19 to 0.39)

1022

(8 studies)

⊕⊕⊕⊝
Moderate 1

‐

Live birth rate

509 per 1000

512 per 1000

(355 to 665)

OR 1.01

(0.53 to 1.91)

182
(1 studies)

⊕⊕⊝⊝
Low 1,2

Clinical pregnancy rate

401 per 1000

352 per 1000

(266 to 450)

OR 0.81

(0.54 to 1.22)

432

(4 studies)

⊕⊕⊕⊝
Moderate 1

Multiple pregnancy

50 per 1000

17 per 1000

(1 to 303)

OR 0.32

(0.01 to 8.26)

40
(1 study)

⊕⊝⊝⊝
Very low 1,3

Miscarriage pregnancy rate

72 per 1000

49 per 1000

(15 to 151)

OR 0.66

(0.19 to 2.28)

168

(2 studies)

⊕⊕⊝⊝
Low 1,4

Adverse events

43 per 1000

168 per 1000

(62 to 381)

OR 4.54

(1.49 to 13.84)

264
(2 studies)

⊕⊝⊝⊝
Very low 1,5

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

ART: assisted reproductive technology; CI: confidence interval; OHSS: ovarian hyperstimulation syndrome; OR: odds ratio.

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 Downgraded one level for serious risk of bias associated with poor reporting of study methods.

2 Downgraded one level for serious risk of imprecision: confidence interval compatible with benefit in either arm or with no difference between the groups.

3 Downgraded two levels for very serious risk of imprecision: only one event.

4 Downgraded one level for serious risk of imprecision: only 10 events.

5 Downgraded one level for serious risk of imprecision: only 29 events.

Figuras y tablas -
Summary of findings for the main comparison. Dopamine agonist versus placebo/no intervention
Ir a la tabla de la revisión
Comparison 1. Dopamine agonist versus placebo/no intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Moderate or severe ovarian hyperstimulation syndrome (OHSS) Show forest plot

8

1022

Odds Ratio (M‐H, Fixed, 95% CI)

0.27 [0.19, 0.39]

1.1 Cabergoline vs placebo/no treatment

5

521

Odds Ratio (M‐H, Fixed, 95% CI)

0.26 [0.16, 0.42]

1.2 Quinagolide vs placebo

2

454

Odds Ratio (M‐H, Fixed, 95% CI)

0.28 [0.15, 0.51]

1.3 Bromocriptine vs placebo (folic acid)

1

47

Odds Ratio (M‐H, Fixed, 95% CI)

0.29 [0.08, 1.14]

2 Subgroup analysis by severity of OHSS Show forest plot

7

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Severe OHSS

7

750

Odds Ratio (M‐H, Fixed, 95% CI)

0.28 [0.14, 0.56]

2.2 Moderate OHSS

7

750

Odds Ratio (M‐H, Fixed, 95% CI)

0.37 [0.24, 0.57]

3 Live birth Show forest plot

1

182

Odds Ratio (M‐H, Fixed, 95% CI)

1.01 [0.53, 1.91]

3.1 Quinagolide vs placebo

1

182

Odds Ratio (M‐H, Fixed, 95% CI)

1.01 [0.53, 1.91]

4 Clinical pregnancy rate Show forest plot

4

432

Odds Ratio (M‐H, Fixed, 95% CI)

0.81 [0.54, 1.22]

4.1 Cabergoline vs no intervention

3

250

Odds Ratio (M‐H, Fixed, 95% CI)

0.81 [0.48, 1.38]

4.2 Quinagolide vs placebo

1

182

Odds Ratio (M‐H, Fixed, 95% CI)

0.81 [0.43, 1.54]

5 Multiple pregnancy Show forest plot

1

40

Odds Ratio (M‐H, Fixed, 95% CI)

0.32 [0.01, 8.26]

5.1 Cabergoline vs placebo/no treatment

1

40

Odds Ratio (M‐H, Fixed, 95% CI)

0.32 [0.01, 8.26]

6 Miscarriage Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Cabergoline vs placebo/no treatment

2

168

Odds Ratio (M‐H, Fixed, 95% CI)

0.66 [0.19, 2.28]

7 Adverse events Show forest plot

2

264

Odds Ratio (M‐H, Fixed, 95% CI)

4.54 [1.49, 13.84]

7.1 Cabergoline vs placebo/no treatment

1

82

Odds Ratio (M‐H, Fixed, 95% CI)

2.24 [0.62, 8.14]

7.2 Quinagolide vs placebo

1

182

Odds Ratio (M‐H, Fixed, 95% CI)

16.64 [0.98, 282.02]
Figuras y tablas -
Comparison 1. Dopamine agonist versus placebo/no intervention
Ir a la tabla de la revisión
Comparison 2. Dopamine agonist plus co‐intervention versus co‐intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Moderate or severe ovarian hyperstimulation syndrome (OHSS) Show forest plot

3

548

Odds Ratio (M‐H, Fixed, 95% CI)

0.57 [0.31, 1.03]

1.1 Cabergoline + albumin vs albumin

1

166

Odds Ratio (M‐H, Fixed, 95% CI)

0.55 [0.23, 1.34]

1.2 Cabergoline + hydroxyethyl starch (HES) vs HES

2

382

Odds Ratio (M‐H, Fixed, 95% CI)

0.58 [0.26, 1.30]

2 Live birth Show forest plot

1

200

Odds Ratio (M‐H, Fixed, 95% CI)

1.04 [0.59, 1.86]

2.1 Cabergoline + HES vs HES

1

200

Odds Ratio (M‐H, Fixed, 95% CI)

1.04 [0.59, 1.86]

3 Clinical pregnancy rate Show forest plot

3

548

Odds Ratio (M‐H, Fixed, 95% CI)

1.0 [0.71, 1.40]

3.1 Cabergoline + albumin vs albumin

1

166

Odds Ratio (M‐H, Fixed, 95% CI)

1.05 [0.56, 1.96]

3.2 Cabergoline + HES vs HES

2

382

Odds Ratio (M‐H, Fixed, 95% CI)

0.98 [0.65, 1.47]

4 Multiple pregnancy Show forest plot

1

166

Odds Ratio (M‐H, Fixed, 95% CI)

2.02 [0.18, 22.77]

4.1 Cabergoline + albumin vs albumin

1

166

Odds Ratio (M‐H, Fixed, 95% CI)

2.02 [0.18, 22.77]

5 Miscarriage Show forest plot

3

548

Odds Ratio (M‐H, Fixed, 95% CI)

0.65 [0.30, 1.42]

5.1 Cabergoline + albumin vs albumin

1

166

Odds Ratio (M‐H, Fixed, 95% CI)

0.33 [0.03, 3.19]

5.2 Cabergoline + HES vs HES

2

382

Odds Ratio (M‐H, Fixed, 95% CI)

0.73 [0.31, 1.68]

6 Adverse events Show forest plot

2

366

Odds Ratio (M‐H, Fixed, 95% CI)

3.03 [0.12, 75.28]

6.1 Cabergoline + albumin vs albumin

1

166

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Cabergoline + HES vs HES

1

200

Odds Ratio (M‐H, Fixed, 95% CI)

3.03 [0.12, 75.28]
Figuras y tablas -
Comparison 2. Dopamine agonist plus co‐intervention versus co‐intervention
Ir a la tabla de la revisión
Comparison 3. Dopamine agonist versus active interventions

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Moderate or severe ovarian hyperstimulation syndrome (OHSS) Show forest plot

6

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Cabergoline vs human albumin

3

296

Odds Ratio (M‐H, Fixed, 95% CI)

0.21 [0.12, 0.38]

1.2 Cabergoline vs prednisolone

1

150

Odds Ratio (M‐H, Fixed, 95% CI)

0.27 [0.05, 1.33]

1.3 Cabergoline vs hydroxyethyl starch (HES)

1

61

Odds Ratio (M‐H, Fixed, 95% CI)

2.69 [0.48, 15.10]

1.4 Cabergoline vs coasting

2

120

Odds Ratio (M‐H, Fixed, 95% CI)

0.50 [0.18, 1.45]

2 Clinical pregnancy rate Show forest plot

3

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Cabergoline vs human albumin

1

140

Odds Ratio (M‐H, Fixed, 95% CI)

0.68 [0.33, 1.38]

2.2 Cabergoline vs coasting

2

120

Odds Ratio (M‐H, Fixed, 95% CI)

2.65 [1.13, 6.21]

3 Multiple pregnancy Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Cabergoline vs human albumin

1

140

Odds Ratio (M‐H, Fixed, 95% CI)

0.58 [0.13, 2.54]

3.2 Cabergoline vs coasting

1

60

Odds Ratio (M‐H, Fixed, 95% CI)

5.35 [0.25, 116.31]

4 Miscarriage Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Cabergoline vs human albumin

1

140

Odds Ratio (M‐H, Fixed, 95% CI)

0.32 [0.03, 3.19]

4.2 Cabergoline vs coasting

1

60

Odds Ratio (M‐H, Fixed, 95% CI)

0.19 [0.01, 4.06]
Figuras y tablas -
Comparison 3. Dopamine agonist versus active interventions
Ir a la tabla de la revisión